Symptoms of alcohol withdrawal syndrome (AWS) may develop within 6-24 h after the abrupt discontinuation or decrease of alcohol consumption. Symptoms can vary from autonomic hyperactivity and agitation to delirium tremens. The gold-standard treatment for AWS is with benzodiazepines (BZDs). Among the BZDs, different agents (i.e., long-acting or short-acting) and different regimens (front-loading, fixed-dose or symptom-triggered) may be chosen on the basis of patient characteristics. Severe withdrawal could require ICU admission and the use of barbiturates or propofol. Other drugs, such as α2-agonists (clonidine and dexmetedomidine) and β-blockers can be used as adjunctive treatments to control neuroautonomic hyperactivity. Furthermore, neuroleptic agents can help control hallucinations. Finally, other medications for the treatment for AWS have been investigated with promising results. These include carbamazepine, valproate, sodium oxybate, baclofen, gabapentin and topiramate. The usefulness of these agents are discussed.

Mirijello, A., D'angelo, C., Ferrulli, A., Vassallo, G. A., Antonelli, M., Caputo, F., Leggio, L., Gasbarrini, A., Addolorato, G., Identification and management of alcohol withdrawal syndrome., <<DRUGS>>, 2015; (75): 353-365 [http://hdl.handle.net/10807/67017]

Identification and management of alcohol withdrawal syndrome.

Mirijello, Antonio;D'Angelo, Cristina;Ferrulli, Anna;Vassallo, Gabriele Angelo;Antonelli, Mariangela;Leggio, Lorenzo;Gasbarrini, Antonio;Addolorato, Giovanni
2015

Abstract

Symptoms of alcohol withdrawal syndrome (AWS) may develop within 6-24 h after the abrupt discontinuation or decrease of alcohol consumption. Symptoms can vary from autonomic hyperactivity and agitation to delirium tremens. The gold-standard treatment for AWS is with benzodiazepines (BZDs). Among the BZDs, different agents (i.e., long-acting or short-acting) and different regimens (front-loading, fixed-dose or symptom-triggered) may be chosen on the basis of patient characteristics. Severe withdrawal could require ICU admission and the use of barbiturates or propofol. Other drugs, such as α2-agonists (clonidine and dexmetedomidine) and β-blockers can be used as adjunctive treatments to control neuroautonomic hyperactivity. Furthermore, neuroleptic agents can help control hallucinations. Finally, other medications for the treatment for AWS have been investigated with promising results. These include carbamazepine, valproate, sodium oxybate, baclofen, gabapentin and topiramate. The usefulness of these agents are discussed.
Inglese
Mirijello, A., D'angelo, C., Ferrulli, A., Vassallo, G. A., Antonelli, M., Caputo, F., Leggio, L., Gasbarrini, A., Addolorato, G., Identification and management of alcohol withdrawal syndrome., <<DRUGS>>, 2015; (75): 353-365 [http://hdl.handle.net/10807/67017]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/67017
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 90
  • ???jsp.display-item.citation.isi??? 78
social impact